Marc Duey Sells 6,462 Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Marc Duey sold 6,462 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the transaction, the director now directly owns 233,651 shares of the company’s stock, valued at $1,070,121.58. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Marc Duey also recently made the following trade(s):

• On Wednesday, October 16th, Marc Duey acquired 30,000 shares of Aprea Therapeutics stock. The shares were purchased at an average cost of $4.39 per share, with a total value of $131,700.00.
• On Monday, October 14th, Marc Duey purchased 190 shares of Aprea Therapeutics stock. The shares were bought at an average price of $2.58 per share, with a total value of $490.20.

Aprea Therapeutics Price Performance

NASDAQ APRE traded up $0.18 during trading hours on Friday, hitting $4.08. The company’s stock had a trading volume of 7,217 shares, compared to its average volume of 20,765. Aprea Therapeutics, Inc. has a 12 month low of $2.15 and a 12 month high of $8.85. The company’s 50 day simple moving average is $3.26 and its two-hundred day simple moving average is $4.11. The company has a market cap of $22.15 million, a P/E ratio of -1.23 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.05. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. The company had revenue of $0.56 million during the quarter, compared to the consensus estimate of $0.10 million. As a group, research analysts predict that Aprea Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on APRE shares. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a report on Thursday.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.